Paranta Biosciences Competitors and Similar CompaniesClear all

Paranta Biosciences's competitors and similar companies include Neo Health, Cipla, EMS Pharma and UCB.

	Paranta Biosciences Paranta Biosciences is a drug development company committed to developing and commercializing biotherapeutics based on recombinant human follistatin to treat conditions involving inflammation and fibrosis.	Neo Health Neo Health (OTC) is a pharmaceutical company delivering over-the-counter medicines, medical devices, and food for medical purposes.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.	EMS Pharma EMS Pharma is a company that specializes in the research, development, and manufacturing of pharmaceuticals.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
Founding Date	Founding Date 2009	Founding Date 2010	Founding Date 1935	Founding Date 1964	Founding Date 1928
Type	Type Private	Type Private	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development medical devices pharma supplements	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Melbourne, AU HQ Prahran, AU	Locations Pennant Hills, AU HQ Castle Hill, AU	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more	Locations BR HQ	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more
Employees	Employees 8	Employees 5	Employees 27,764	Employees 12,7441% increase	Employees 9,052
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)	Revenue (est.) N/A	Revenue (est.) €7.4b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods ₹95.5b (FY, 2026)	Cost of goods N/A	Cost of goods €1.4b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit ₹195b (FY, 2026)	Gross profit N/A	Gross profit €7.2b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income ₹38.7b (FY, 2026)	Net income N/A	Net income €1.6b (FY, 2025)
Operating ⚠
Products	Products N/A	Products 250 (Nov, 2020)	Products 1.5 k (FY, 2024)	Products N/A	Products N/A